Evidence Hub

Tinea Capitis Caused by Trichophyton tonsurans That Responded to Fosravuconazole: The First Detailed Report

Ayaka Miyata, Utako Kimura, Hiromitsu Noguchi, Masataro Hiruma, Rui Kano, Yasushi Suga

Medical Mycology Journal, 2025

1 citation

Abstract

We herein report the first case of tinea capitis caused by Trichophyton tonsurans that responded to fosravuconazole (F-RVCZ). Clinical improvement was achieved within six weeks after the start of F-RVCZ therapy, and the hairbrush culture test was negative. After treatment discontinuation, no relapse of symptoms was observed, and subsequent hairbrush cultures remained negative. F-RVCZ has been suggested as a rapidly acting and effective therapeutic agent for tinea capitis caused by this infection. Treatment of tinea capitis requires oral antifungal therapy; however, side effects associated with long-term administration sometimes occur. Oral treatment with F-RVCZ was found to be effective and had the advantage of relatively few side effects.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free